Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina.

IF 2 Q4 VIROLOGY
Frontiers in virology Pub Date : 2023-01-01 Epub Date: 2023-02-28 DOI:10.3389/fviro.2023.1108420
Jennifer Tisoncik-Go, Kathleen M Voss, Thomas B Lewis, Antonio E Muruato, LaRene Kuller, Eric E Finn, Dillon Betancourt, Solomon Wangari, Joel Ahrens, Naoto Iwayama, Richard F Grant, Robert D Murnane, Paul T Edlefsen, Deborah H Fuller, Glen N Barber, Michael Gale, Megan A O'Connor
{"title":"Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina.","authors":"Jennifer Tisoncik-Go, Kathleen M Voss, Thomas B Lewis, Antonio E Muruato, LaRene Kuller, Eric E Finn, Dillon Betancourt, Solomon Wangari, Joel Ahrens, Naoto Iwayama, Richard F Grant, Robert D Murnane, Paul T Edlefsen, Deborah H Fuller, Glen N Barber, Michael Gale, Megan A O'Connor","doi":"10.3389/fviro.2023.1108420","DOIUrl":null,"url":null,"abstract":"<p><p>Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (VSV-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model.</p>","PeriodicalId":73114,"journal":{"name":"Frontiers in virology","volume":"3 ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306241/pdf/nihms-1902797.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in virology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fviro.2023.1108420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Zika virus (ZIKV) is a mosquito-borne flavivirus that causes an acute febrile illness. ZIKV can be transmitted between sexual partners and from mother to fetus. Infection is strongly associated with neurologic complications in adults, including Guillain-Barré syndrome and myelitis, and congenital ZIKV infection can result in fetal injury and congenital Zika syndrome (CZS). Development of an effective vaccine is imperative to protect against ZIKV vertical transmission and CZS. Recombinant Vesicular Stomatitis virus (rVSV) is a highly effective and safe vector for the delivery of foreign immunogens for vaccine purposes. Here, we evaluate an rVSV vaccine expressing the full length pre-membrane (prM) and ZIKV envelope (E) proteins (VSV-ZprME), shown to be immunogenic in murine models of ZIKV infection, for its capacity to induce immune responses in nonhuman primates. Moreover, we assess the efficacy of the rVSVΔM-ZprME vaccine in the protection of pigtail macaques against ZIKV infection. Administration of the rVSVΔM-ZprME vaccine was safe, but it did not induce robust anti-ZIKV T-cell responses, IgM or IgG antibodies, or neutralizing antibodies in most animals. Post ZIKV challenge, animals that received the rVSVΔM control vaccine lacking ZIKV antigen had higher levels of plasma viremia compared to animals that received the rVSVΔM-ZprME vaccine. Anti-ZIKV neutralizing Ab titers were detected in a single animal that received the rVSVΔM-ZprME vaccine that was associated with reduced plasma viremia. The overall suboptimal ZIKV-specific cellular and humoral responses post-immunization indicates the rVSVΔM-ZprME vaccine did not elicit an immune response in this pilot study. However, recall antibody response to the rVSVΔM-ZprME vaccine indicates it may be immunogenic and further developments to the vaccine construct could enhance its potential as a vaccine candidate in a nonhuman primate pre-clinical model.

评估rVSV疫苗对猕猴寨卡病毒感染的免疫原性和有效性。
寨卡病毒(ZIKV)是一种由蚊子传播的黄病毒,可引起急性发热性疾病。寨卡病毒可在性伴侣之间传播,也可由母亲传染给胎儿。感染与成人神经系统并发症(包括格林-巴利综合征和脊髓炎)密切相关,先天性 ZIKV 感染可导致胎儿损伤和先天性寨卡综合征 (CZS)。为预防 ZIKV 垂直传播和先天性寨卡综合症,开发有效的疫苗势在必行。重组水泡性口炎病毒(rVSV)是一种高效、安全的载体,可将外来免疫原输送到疫苗中。在这里,我们评估了一种表达全长前膜(prM)和 ZIKV 包膜(E)蛋白(VSV-ZprME)的 rVSV 疫苗在非人灵长类动物中诱导免疫反应的能力。此外,我们还评估了 rVSVΔM-ZprME 疫苗在保护猪尾猕猴免受 ZIKV 感染方面的功效。接种rVSVΔM-ZprME疫苗是安全的,但它并不能在大多数动物体内诱导出强大的抗ZIKV T细胞反应、IgM或IgG抗体或中和抗体。ZIKV挑战后,与接种rVSVΔM-ZprME疫苗的动物相比,接种缺乏ZIKV抗原的rVSVΔM对照疫苗的动物血浆病毒血症水平更高。在接种 rVSVΔM-ZprME 疫苗的一只动物体内检测到了抗 ZIKV 中和抗体滴度,这与血浆病毒血症的降低有关。免疫后 ZIKV 特异性细胞和体液反应的总体情况欠佳表明,在这项试验研究中,rVSVΔM-ZprME 疫苗没有引起免疫反应。不过,对 rVSVΔM-ZprME 疫苗的抗体反应回顾表明它可能具有免疫原性,疫苗结构的进一步发展可以提高它作为非人灵长类动物临床前模型候选疫苗的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信